Insights

Gathering insights about Logic…

Similar companies to Logic

Logic Tech Stack

Logic uses 5 technology products and services including Snowplow, Google Font API, jQuery, and more. Explore Logic's tech stack below.

Snowplow
Analytics
Google Font API
Font Scripts
jQuery
Javascript Libraries
Amazon Web Services
Platform As A Service
reCAPTCHA
Security

Media & News

Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer
ROCKVILLE, Md., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the outcomes of a recent Type D meeting with the U.S. Food and Drug Administration (FDA) to obtain guidance on the design of a Phase 3 clinical study of lead clinical candidate VCN-01 in combination with standard-of-care chemotherapy for the treatment of metastatic pancreatic adenocarcinoma (PDAC). The Company recently announced the completion of target enrollment into the multinational VIRAGE Phase 2b clinical study evaluating intravenous VCN-01 in combination with gemcitabine/nab-paclitaxel as a first line therapy for PDAC patients.
Dec 05, 2024 | www.globenewswire.com
Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma
ROCKVILLE, Md., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that the European Commission has adopted the European Medicines Agency (EMA) recommendation to grant orphan medicinal product designation to lead clinical candidate VCN-01, Theriva's systemic, selective, stroma-degrading oncolytic adenovirus, for the treatment of retinoblastoma. The United States Food and Drug Administration (FDA) has previously granted orphan drug designation and rare pediatric disease designation to VCN-01 for the treatment of retinoblastoma.
Oct 16, 2024 | www.globenewswire.com
Theriva Biologics Announces Pricing of $2.5 Million Public Offering
ROCKVILLE, Md., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American: TOVX) (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the pricing of its “reasonable best efforts” public offering for the purchase and sale of up to 1,428,600 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 1,428,600 shares of common stock at a combined offering price of $1.75 per share and accompanying warrant (the “Offering”). The Company expects to receive aggregate gross proceeds of approximately $2.5 million, before deducting placement agent fees and other offering expenses, and assuming no exercise of the warrants. The warrants will have an exercise price of $2.00 per share, will be exercisable immediately and will expire five years from the issuance date.
Sep 26, 2024 | www.globenewswire.com
Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- Target of 92 evaluable patients (46 in each of the control and VCN-01 treatment arms) enrolled across 15 sites in Spain and the USA within 21 months –
Sep 23, 2024 | www.globenewswire.com
Theriva™ Biologics Awarded Manufacturing Funding from the Spanish Government's National Knowledge Transfer Program
Theriva Biologics and the Universitat Autònoma de Barcelona to receive a total of €2.28 Million to support the THERICEL project, a suspension cell platform for manufacturing viral-based therapies Theriva Biologics and the Universitat Autònoma de Barcelona to receive a total of €2.28 Million to support the THERICEL project, a suspension cell platform for manufacturing viral-based therapies
Sep 16, 2024 | www.globenewswire.com
Theriva Biologics Announces Reverse Stock Split
ROCKVILLE, Md., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, announced today a reverse stock split of its issued and outstanding common stock, par value $0.001 per share, at a ratio of one (1) share of common stock for every twenty five (25) shares of common stock, effective as of 12:01 a.m. (Eastern Time) on August 26, 2024 (the “Effective Date”). The Company's common stock will begin trading on a split-adjusted basis when the market opens on August 26, 2024. The reverse stock split was authorized by the Company's Board of Directors on August 15, 2024. Pursuant to the laws of the State of Nevada, the Company's state of incorporation, the Company's Board of Directors has the authority to effect a reverse stock split without shareholder approval if the number of authorized shares of common stock and the number of outstanding shares of common stock are proportionally reduced. The Company will file a certificate of change to its articles of incorporation, as amended, with the Secretary of State of Nevada to effect the reverse stock split. The Company's common stock will continue to trade on the NYSE American under the stock ticker “TOVX” but will trade under the new CUSIP number 87164U 508.
Aug 16, 2024 | www.globenewswire.com
Theriva™ Biologics Receives Rare Pediatric Drug Designation by the U.S. FDA for VCN-01 for the Treatment of Retinoblastoma
ROCKVILLE, Md., July 31, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Drug Designation (RPDD) for VCN-01 for the treatment of retinoblastoma. VCN-01, Theriva's lead product candidate, is a systemic, selective, stroma-degrading oncolytic adenovirus. Previously, the FDA granted orphan drug designation to VCN-01 for treatment of retinoblastoma.
Jul 31, 2024 | www.globenewswire.com

Logic's Email Address Formats

Logic uses at least 1 format(s):

Logic Email Formats	Example	Percentage
FLast@logiclc.com	JDoe@logiclc.com	50%
FLast@logiclc.com	JDoe@logiclc.com	50%

Frequently Asked Questions

Where is Logic's headquarters located?

Logic's main headquarters is located at 2 Bala Plaza Suite 300 Bala-Cynwyd, Pennsylvania 19004 US. The company has employees across 2 continents, including North AmericaEurope.

What is Logic's stock symbol?

Logic is a publicly traded company; the company's stock symbol is TOVX.

What is Logic's official website and social media links?

Logic's official website is logiclc.com and has social profiles on LinkedIn.

How much revenue does Logic generate?

As of May 2024, Logic's annual revenue reached $3.8M.

What is Logic's NAICS code?

Logic's NAICS code is 5415 - Computer Systems Design and Related Services.

How many employees does Logic have currently?

As of May 2024, Logic has approximately 201 employees across 2 continents, including North AmericaEurope. Key team members include Chief Customer Officer: P. E. S.Vice President Of Sales And Marketing: A. C.Vice President Of Recruiting, Sourcing And People: D. L.. Explore Logic's employee directory with LeadIQ.

What industry does Logic belong to?

Logic operates in the IT Services and IT Consulting industry.

What technology does Logic use?

Logic's tech stack includes SnowplowGoogle Font APIjQueryAmazon Web ServicesreCAPTCHA.

What is Logic's email format?

Logic's email format typically follows the pattern of . Find more Logic email formats with LeadIQ.

When was Logic founded?

Logic was founded in 2008.

Logic

IT Services and IT ConsultingPennsylvania, United States201-500 Employees

Logic is proud to deliver outstanding value to businesses using the latest technology and custom IT solutions in the Philadelphia Region and Nationwide.
  
Some of the Services we Provide, Include:

•	Network Design & Building 
•	Video Surveillance & Access Control 
•	Wi-Fi Engineering & Low Voltage Cabling
•	Data Security & Cloud Solutions
•	Business VoIP Phone Systems
•	Hardware & Multi-Function Printers

Contact us for a free consultation.  A member of our team will explain how these Services are highly complementary to one another and together create value for our Client’s that could never be achieved otherwise.  We understand and support all areas of your IT systems from back-end infrastructure to front-end personal productivity.  We set ourselves apart from the competition using “logic” in our approach. 

Call us today 484-452-2435
THE BUSINESS PARTNER FOR ALL OF YOUR IT NEEDS.